207 related articles for article (PubMed ID: 25208121)
61. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Ying Z; Zhang CH; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Mar; 38(3):409-18. PubMed ID: 9074529
[TBL] [Abstract][Full Text] [Related]
62. Current status of cancer therapy with radiolabeled monoclonal antibody.
Oriuchi N; Higuchi T; Hanaoka H; Iida Y; Endo K
Ann Nucl Med; 2005 Jul; 19(5):355-65. PubMed ID: 16164191
[TBL] [Abstract][Full Text] [Related]
63. Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer.
Muto MG; Kassis AI
Cancer; 1995 Nov; 76(10 Suppl):2016-27. PubMed ID: 8634994
[TBL] [Abstract][Full Text] [Related]
64. Diagnostic and therapeutic applications of monoclonal antibodies in colorectal cancer.
Stocchi L; Nelson H
Dis Colon Rectum; 1998 Feb; 41(2):232-50. PubMed ID: 9556250
[TBL] [Abstract][Full Text] [Related]
65. CaNa2EDTA for improvement of radioimmunodetection and radioimmunotherapy with 111In and 90Y-DTPA-anti-CEA MAbs in nude mice bearing human colorectal cancer.
Watanabe N; Oriuchi N; Endo K; Inoue T; Kuroki M; Matsuoka Y; Tanada S; Murata H; Kim EE; Sasaki Y
J Nucl Med; 2000 Feb; 41(2):337-44. PubMed ID: 10688120
[TBL] [Abstract][Full Text] [Related]
66. Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling.
Wang Z; Mårtensson L; Nilsson R; Bendahl PO; Lindgren L; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7171s-7177s. PubMed ID: 16203818
[TBL] [Abstract][Full Text] [Related]
67. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
[TBL] [Abstract][Full Text] [Related]
68. Immunoscintigraphy of infections using 123I and 99mTc-labeled monoclonal antibodies. Advanced experiences in 230 patients.
Seybold K; Frey LD; Locher J
Angiology; 1992 Feb; 43(2):85-90. PubMed ID: 1536479
[TBL] [Abstract][Full Text] [Related]
69. In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand.
Milenic DE; Roselli M; Brechbiel MW; Pippin CG; McMurray TJ; Carrasquillo JA; Colcher D; Lambrecht R; Gansow OA; Schlom J
Eur J Nucl Med; 1998 May; 25(5):471-80. PubMed ID: 9575242
[TBL] [Abstract][Full Text] [Related]
70. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
Goldenberg DM; Sharkey RM; Paganelli G; Barbet J; Chatal JF
J Clin Oncol; 2006 Feb; 24(5):823-34. PubMed ID: 16380412
[TBL] [Abstract][Full Text] [Related]
71. Experimental radioimmunotherapy.
Buchsbaum DJ; Langmuir VK; Wessels BW
Med Phys; 1993; 20(2 Pt 2):551-67. PubMed ID: 8492764
[TBL] [Abstract][Full Text] [Related]
72. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies.
Zhu H; Baxter LT; Jain RK
J Nucl Med; 1997 May; 38(5):731-41. PubMed ID: 9170438
[TBL] [Abstract][Full Text] [Related]
73. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis.
Knogler K; Grünberg J; Zimmermann K; Cohrs S; Honer M; Ametamey S; Altevogt P; Fogel M; Schubiger PA; Novak-Hofer I
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):603-11. PubMed ID: 17255283
[TBL] [Abstract][Full Text] [Related]
74. Animal models for radiolabeled monoclonal antibodies in cancer research.
Aas M; Fjeld JG
Acta Oncol; 1993; 32(7-8):819-24. PubMed ID: 8305231
[TBL] [Abstract][Full Text] [Related]
75. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors.
Larson SM; Macapinlac HA; Scott AM; Divgi CR
Acta Oncol; 1993; 32(7-8):709-15. PubMed ID: 8305216
[TBL] [Abstract][Full Text] [Related]
76. [Direct and indirect labeling with 99mTc of an antireceptor monoclonal antibody of EGF].
Calderón Sánchez O; Zayas Crespo F; Leyva Montaña R; Beckford Vera D; Gómez JA
Rev Esp Med Nucl; 2005; 24(1):38-44. PubMed ID: 15701345
[TBL] [Abstract][Full Text] [Related]
77. A model for others: a strategy for improving diagnosis and therapy of human malignancies using monoclonal antibodies targeting TAG-72 oncofetal antigen.
Larson SM
Cancer Invest; 1993; 11(2):235-8. PubMed ID: 8462025
[No Abstract] [Full Text] [Related]
78. Radioimmunolocalization of primary and metastatic breast cancer.
Baum RP; Brümmendorf TH
Q J Nucl Med; 1998 Mar; 42(1):33-42. PubMed ID: 9646643
[TBL] [Abstract][Full Text] [Related]
79. [Pilot study with the monoclonal antibody IOR-C5 as a potential agent of radioimmunoscintigraphy in colorectal cancer].
Oliva JP; Pimentel G; Borrón M; Peralta R; Ortiz R; Oliver B; Díaz N; Sánchez I; Vázquez AM; Baum RP
Rev Esp Med Nucl; 2001 Jun; 20(4):282-8. PubMed ID: 11940415
[TBL] [Abstract][Full Text] [Related]
80. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
Kawashima H
ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
